AbbVie submitted a New Drug Application to the U.S. Food and Drug Administration for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

Cerebras Systems, a pioneer in high performance artificial intelligence (AI) computing, and AbbVie, a global biopharmaceutical company, announced a landmark achievement in AbbVie’s AI work.

AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.

Plexium Inc. and AbbVie Inc. entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.

hydrocodone

Pharmacy chain Walgreens Boots Alliance and other defendants on April 26 said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain.

Walgreens Boots Alliance and Teva Pharmaceutical Industries Ltd. ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on April 25 during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.

AbbVie

AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.

Johnson & Johnson agreed to pay $99 million to settle claims by West Virginia that it helped fuel an opioid addiction crisis in the state, removing the company from an ongoing trial that began earlier in April.

AbbVie company Allergan Aesthetics announced the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April 15, 2022, marks 20 years since the U.S. Food and Drug Administration first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between your eyebrows.

West Virginia’s attorney general on April 4 urged a judge to hold Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.’s Allergen liable for causing a “tsunami” of opioid addiction in the state.